News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Boehringer Ingelheim Corporation Announces Initiation of Pivotal Trial Investigating Volasertib in Patients With Acute Myeloid Leukaemia



2/28/2013 9:59:15 AM

INGELHEIM, Germany--(BUSINESS WIRE)--With the enrollment of the first patient, Boehringer Ingelheim is pleased to announce on international Rare Disease Day, the initiation of a Phase III study (POLO-AML-2) investigating volasertib*, a selective and potent polo-like kinase (Plk) inhibitor, in combination with chemotherapy, in patients with acute myeloid leukaemia (AML) ineligible for intensive therapy. Acute leukaemias are rare diseases, with AML being the most deadly acute leukaemia in adults.1 Today marks the sixth international Rare Disease Day, and more than 60 countries around the world will join to raise awareness for those affected by rare diseases. In Europe, rare disease is defined as a life-threatening or chronically debilitating disease which affects fewer than five people per 10,000.2

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES